Clinical trials: Neoplasm, Oral
Oral Mucositis, Periodontal Diseases
F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)
The investigators will conduct a 2-arm 6-month randomized clinical controlled trial to evaluate the effectiveness of an oral Telehealth Intervention (THI) in preventing cancer-related oral complications, improving oral health…
- Conditions
- Oral Mucositis, Periodontal Diseases, Cancer
- Trial name
- NCT06315855
- Testing
- Telehealth Intervention (THI)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Georgetown University
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
The working hypothesis is that oral rigosertib treatment when added to platinum-based Chemoradiotherapy (CRT) will improve progression-free survival for first-line patients with intermediate- or high-risk human papillomavirus…
- Trial name
- NCT02107235
- Testing
- oral rigosertib, cisplatin, Radiotherapy
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Traws Pharma, Inc.
Solid Tumor With p53 Wild Type Status
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
This is a first in human phase I study of single agent CGM097 in patients with advanced solid tumors who have progressed despite standard therapy or for whom no standard therapy exists.
- Trial name
- CCGM097X2101 (NCT01760525)
- Testing
- CGM097
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Digestive Cancer
Association Between Composition of the Gut Microbiota and Nutritional Status in Digestive Oncology
Nutritional status represents a crucial issue in the management of cancer patients, as between 40% and 60% of them suffer from malnutrition at the time of diagnosis.
- Trial name
- ONCONUTRIBIOTA (NCT07260617)
- Testing
- Not applicable- observational study
- Where
- 3 sites in France
- Volunteers
- 150 people
- Sponsor
- Hospices Civils de Lyon
Non-small Cell Lung Cancer
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: Cohort I: Patients previously treated…
- Trial name
- NCT00359450
- Testing
- BMS-275183 (oral taxane)
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 186 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Cancer, Oropharyngeal Carcinoma
Thermotherapy for Head and Neck Cancer Patients
This phase I, single-center study evaluates the safety, tolerability, and recommended phase II dose (RP2D) of mild hyperthermia (thermotherapy) when added to standard-of-care treatment in patients with locally advanced head and…
- Conditions
- Head and Neck Cancer, Oropharyngeal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma
- Trial name
- TANCAP-I (NCT07690618)
- Testing
- Thermotherapy, Radiotherapy, Concurrent chemoradiation
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
Leiomyoma
Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670
Effects of BAY1002670 on bleeding pattern: non-bleeding rate; on endometrium; on ovarian function; return of menstrual bleeding after treatment; safety and tolerability; PK/PD (pharmacokinetic/pharmacodynamic) relationship
- Trial name
- NCT01816815
- Testing
- BAY1002670
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Bayer
Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
- Trial name
- NCT01106508
- Testing
- LEQ506
- Where
- 5 sites in United States, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
This is a phase II randomized, open label study of durvalumab with/ without tremelimumab as neoadjuvant therapy and durvalumab maintenance after SoC RTx with/without cisplatin as post-surgical adjuvant therapy in treatment naïve…
- Conditions
- Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx, Larynx
- Trial name
- NCT03737968
- Testing
- Durvalumab, durvalumab + tremelimumab
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Lung Cancer
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00028925
- Testing
- filgrastim, carboplatin, topotecan hydrochloride
- Where
- 24 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Head and Neck Cancer
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00425750
- Testing
- bortezomib, docetaxel, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Radiotherapy-induced Oral Mucositis
Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.
Evaluate the effectiveness and safety of traditional Chinese medicine compound in improving radiotherapy-induced oral mucositis in patients with head and neck malignant tumors.
- Trial name
- NCT07339774
- Testing
- Zishui Daohuo oral liquid combined with Kujiu mouthwash, Radiotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- West China Hospital
Tumors, Cutaneous T-Cell Lymphoma
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma
- Trial name
- NCT00412997
- Testing
- LBH589
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Novartis
Melanoma (Skin)
Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of tretinoin and/or fenretinide may be an effective way to prevent the recurrence or further…
- Trial name
- NCT00003601
- Testing
- fenretinide, tretinoin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Eastern Cooperative Oncology Group
Solid Tumors
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.
- Trial name
- NCT02063230
- Testing
- Selumetinib 50mg, Selumetinib 25mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Breast Neoplasms
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
To evaluate the preliminary activity and pharmacokinetics of 2 separate doses and schedules of orally administered Temsirolimus (CCI-779) given in combination with daily letrozole, compared to letrozole alone, in the treatment of…
- Trial name
- NCT00062751
- Testing
- Letrozole / Temsirolimus (CCI-779), Letrozole
- Volunteers
- 108 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Squamous Cell Carcinoma of the Oral Cavity
Contribution of Residual Tumour DNA Testing on the Surgical Bed
The aim of this study is to evaluate the interest of residual tumour DNA research in the operating bed after squamous cell carcinoma excision.
- Trial name
- MARGINS (NCT05934929)
- Testing
- Circulating tumor DNA detection
- Where
- 2 sites in France
- Volunteers
- 31 people
- Sponsor
- Centre Henri Becquerel
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT05024045
- Testing
- LOXO-338, Pirtobrutinib
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Genital Neoplasms, Female
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
- Trial name
- NCT02182245
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
Salivary Cytokines as Biomarker for Oral Health
Oral complications during and after cancer treatment are common. A key role in maintaining oral health plays saliva. In the last decade numerous studies have investigated immunological biomarkers such as cytokines in saliva…
- Trial name
- Cytosal (NCT02807519)
- Testing
- collection of salivary cytokines
- Where
- 3 sites in Switzerland
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland